Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-Current Assets for 10 consecutive years, with $48.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 43.26% to $48.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $197.2 million, a 42.99% decrease, with the full-year FY2024 number at $48.5 million, down 44.69% from a year prior.
  • Non-Current Assets was $48.5 million for Q3 2025 at Rein Therapeutics, down from $50.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $87.7 million in Q4 2023 to a low of $29000.0 in Q3 2023.
  • A 5-year average of $28.7 million and a median of $347000.0 in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 94.81% in 2021, then skyrocketed 294841.38% in 2024.
  • Rein Therapeutics' Non-Current Assets stood at $304000.0 in 2021, then tumbled by 55.92% to $134000.0 in 2022, then soared by 65379.1% to $87.7 million in 2023, then crashed by 44.69% to $48.5 million in 2024, then decreased by 0.0% to $48.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Non-Current Assets are $48.5 million (Q3 2025), $50.9 million (Q2 2025), and $49.3 million (Q1 2025).